---
layout: default
title: EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment
---

# EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2512.14019" class="toolbar-btn" target="_blank">ğŸ“„ arXiv: 2512.14019</a>
  <a href="https://arxiv.org/pdf/2512.14019.pdf" class="toolbar-btn" target="_blank">ğŸ“¥ PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2512.14019" onclick="toggleFavorite(this, '2512.14019', 'EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment')" title="æ·»åŠ åˆ°æ”¶è—å¤¹">â˜† æ”¶è—</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">ğŸ”— åˆ†äº«</button>
</div>


**ä½œè€…**: Juseung Yun, Sunwoo Yu, Sumin Ha, Jonghyun Kim, Janghyeon Lee, Jongseong Jang, Soonyoung Lee

**åˆ†ç±»**: cs.LG, bio.QM

**å‘å¸ƒæ—¥æœŸ**: 2025-12-18

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

**EXAONE Path 2.5ï¼šå¤šç»„å­¦å¯¹é½çš„ç—…ç†å­¦åŸºç¡€æ¨¡å‹ï¼Œç”¨äºæ›´å…¨é¢çš„è‚¿ç˜¤ç”Ÿç‰©å­¦ç†è§£ã€‚**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **æ”¯æŸ±äºŒï¼šRLç®—æ³•ä¸æ¶æ„ (RL & Architecture)** **æ”¯æŸ±ä¹ï¼šå…·èº«å¤§æ¨¡å‹ (Embodied Foundation Models)**

**å…³é”®è¯**: `ç—…ç†å­¦` `å¤šç»„å­¦` `åŸºç¡€æ¨¡å‹` `å¯¹æ¯”å­¦ä¹ ` `ç²¾å‡†è‚¿ç˜¤å­¦`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. ç°æœ‰ç—…ç†å­¦æ¨¡å‹ä¸»è¦ä¾èµ–å›¾åƒä¿¡æ¯ï¼Œå¿½ç•¥äº†åŸºå› ç»„å­¦ã€è¡¨è§‚åŸºå› ç»„å­¦ç­‰åˆ†å­å±‚é¢çš„ä¿¡æ¯ï¼Œé™åˆ¶äº†å¯¹è‚¿ç˜¤ç”Ÿç‰©å­¦çš„å…¨é¢ç†è§£ã€‚
2. EXAONE Path 2.5é€šè¿‡å¤šæ¨¡æ€SigLIPæŸå¤±ã€ç‰‡æ®µæ„ŸçŸ¥æ—‹è½¬ä½ç½®ç¼–ç å’Œé¢†åŸŸä¸“ç”¨å†…éƒ¨åŸºç¡€æ¨¡å‹ï¼Œå®ç°ç»„ç»‡å­¦ã€åŸºå› ç»„å­¦ç­‰å¤šç»„å­¦ä¿¡æ¯çš„è”åˆå»ºæ¨¡ã€‚
3. å®éªŒç»“æœè¡¨æ˜ï¼ŒEXAONE Path 2.5åœ¨Patho-Benchä¸Šè¾¾åˆ°SOTAæ€§èƒ½ï¼Œå¹¶åœ¨å†…éƒ¨ä¸´åºŠæ•°æ®é›†ä¸­è¡¨ç°å‡ºæ›´é«˜çš„é€‚åº”æ€§ï¼ŒéªŒè¯äº†å¤šæ¨¡æ€å»ºæ¨¡çš„æœ‰æ•ˆæ€§ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ç™Œç—‡è¿›å±•æºäºå¤šä¸ªç”Ÿç‰©å±‚é¢çš„ç›¸äº’ä½œç”¨ï¼Œç‰¹åˆ«æ˜¯å½¢æ€å­¦ä¹‹å¤–ä»¥åŠåˆ†å­å±‚é¢çš„ç›¸äº’ä½œç”¨ï¼Œè¿™äº›ç›¸äº’ä½œç”¨å¯¹äºä»…ä½¿ç”¨å›¾åƒçš„æ¨¡å‹æ¥è¯´æ˜¯ä¸å¯è§çš„ã€‚ä¸ºäº†æ•æ‰æ›´å¹¿æ³›çš„ç”Ÿç‰©å­¦å›¾æ™¯ï¼Œæˆ‘ä»¬æå‡ºäº†EXAONE Path 2.5ï¼Œè¿™æ˜¯ä¸€ä¸ªç—…ç†å­¦åŸºç¡€æ¨¡å‹ï¼Œå®ƒè”åˆå»ºæ¨¡ç»„ç»‡å­¦ã€åŸºå› ç»„å­¦ã€è¡¨è§‚åŸºå› ç»„å­¦å’Œè½¬å½•ç»„å­¦æ¨¡æ€ï¼Œäº§ç”Ÿä¸€ä¸ªç»¼åˆçš„æ‚£è€…è¡¨å¾ï¼Œæ›´å…¨é¢åœ°åæ˜ è‚¿ç˜¤ç”Ÿç‰©å­¦ã€‚æˆ‘ä»¬çš„æ–¹æ³•åŒ…å«ä¸‰ä¸ªå…³é”®ç»„æˆéƒ¨åˆ†ï¼šï¼ˆ1ï¼‰å¤šæ¨¡æ€SigLIPæŸå¤±ï¼Œæ”¯æŒè·¨å¼‚æ„æ¨¡æ€çš„æ‰€æœ‰æˆå¯¹å¯¹æ¯”å­¦ä¹ ï¼›ï¼ˆ2ï¼‰ç‰‡æ®µæ„ŸçŸ¥æ—‹è½¬ä½ç½®ç¼–ç ï¼ˆF-RoPEï¼‰æ¨¡å—ï¼Œåœ¨WSIä¸­ä¿ç•™ç©ºé—´ç»“æ„å’Œç»„ç»‡ç‰‡æ®µæ‹“æ‰‘ï¼›ï¼ˆ3ï¼‰WSIå’ŒRNA-seqçš„é¢†åŸŸä¸“ç”¨å†…éƒ¨åŸºç¡€æ¨¡å‹ï¼Œä¸ºç¨³å¥çš„å¤šæ¨¡æ€å¯¹é½æä¾›ç”Ÿç‰©å­¦åŸºç¡€çš„åµŒå…¥ã€‚æˆ‘ä»¬åœ¨ä¸¤ä¸ªäº’è¡¥çš„åŸºå‡†ä¸Šè¯„ä¼°äº†EXAONE Path 2.5ï¼Œä¸€ä¸ªæ˜¯å†…éƒ¨çœŸå®ä¸´åºŠæ•°æ®é›†ï¼Œå¦ä¸€ä¸ªæ˜¯æ¶µç›–80ä¸ªä»»åŠ¡çš„Patho-BenchåŸºå‡†ï¼Œå¹¶ä¸å…­ä¸ªé¢†å…ˆçš„ç—…ç†å­¦åŸºç¡€æ¨¡å‹è¿›è¡Œäº†æ¯”è¾ƒã€‚æˆ‘ä»¬çš„æ¡†æ¶å±•ç¤ºäº†é«˜æ•°æ®å’Œå‚æ•°æ•ˆç‡ï¼Œåœ¨Patho-Benchä¸Šå®ç°äº†ä¸æœ€å…ˆè¿›çš„åŸºç¡€æ¨¡å‹ç›¸å½“çš„æ€§èƒ½ï¼ŒåŒæ—¶åœ¨å†…éƒ¨ä¸´åºŠç¯å¢ƒä¸­è¡¨ç°å‡ºæœ€é«˜çš„é€‚åº”æ€§ã€‚è¿™äº›ç»“æœçªå‡ºäº†ç”Ÿç‰©ä¿¡æ¯å¤šæ¨¡æ€è®¾è®¡çš„ä»·å€¼ï¼Œå¹¶å¼ºè°ƒäº†ç”¨äºä¸‹ä¸€ä»£ç²¾å‡†è‚¿ç˜¤å­¦çš„æ•´åˆåŸºå› å‹åˆ°è¡¨å‹å»ºæ¨¡çš„æ½œåŠ›ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šç°æœ‰ç—…ç†å­¦åŸºç¡€æ¨¡å‹ä¸»è¦ä¾èµ–äºç»„ç»‡ç—…ç†å­¦å›¾åƒï¼Œå¿½ç•¥äº†åŸºå› ç»„å­¦ã€è¡¨è§‚åŸºå› ç»„å­¦å’Œè½¬å½•ç»„å­¦ç­‰å…¶ä»–é‡è¦çš„ç”Ÿç‰©å­¦ä¿¡æ¯ã€‚è¿™å¯¼è‡´æ¨¡å‹æ— æ³•å…¨é¢ç†è§£è‚¿ç˜¤çš„å¤æ‚ç”Ÿç‰©å­¦æœºåˆ¶ï¼Œé™åˆ¶äº†å…¶åœ¨ç²¾å‡†è‚¿ç˜¤å­¦ä¸­çš„åº”ç”¨ã€‚ç°æœ‰æ–¹æ³•éš¾ä»¥æœ‰æ•ˆåœ°æ•´åˆè¿™äº›å¼‚æ„æ•°æ®ï¼Œå¹¶ä¸”ç¼ºä¹å¯¹ç»„ç»‡ç©ºé—´ç»“æ„çš„æœ‰æ•ˆå»ºæ¨¡ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šEXAONE Path 2.5çš„æ ¸å¿ƒæ€è·¯æ˜¯å°†ç»„ç»‡ç—…ç†å­¦å›¾åƒä¸åŸºå› ç»„å­¦ã€è¡¨è§‚åŸºå› ç»„å­¦å’Œè½¬å½•ç»„å­¦æ•°æ®è¿›è¡Œè”åˆå»ºæ¨¡ï¼Œä»è€Œè·å¾—ä¸€ä¸ªæ›´å…¨é¢çš„æ‚£è€…è¡¨å¾ã€‚é€šè¿‡å¤šæ¨¡æ€å¯¹æ¯”å­¦ä¹ ï¼Œæ¨¡å‹èƒ½å¤Ÿå­¦ä¹ åˆ°ä¸åŒæ¨¡æ€ä¹‹é—´çš„å…³è”ï¼Œä»è€Œæ›´å¥½åœ°ç†è§£è‚¿ç˜¤çš„ç”Ÿç‰©å­¦ç‰¹æ€§ã€‚åŒæ—¶ï¼Œæ¨¡å‹è¿˜è€ƒè™‘äº†ç»„ç»‡çš„ç©ºé—´ç»“æ„ï¼Œä»¥æ›´å¥½åœ°æ•æ‰è‚¿ç˜¤çš„å¾®ç¯å¢ƒä¿¡æ¯ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šEXAONE Path 2.5çš„æŠ€æœ¯æ¡†æ¶ä¸»è¦åŒ…å«ä¸‰ä¸ªæ¨¡å—ï¼š1) å¤šæ¨¡æ€SigLIPæŸå¤±ï¼šç”¨äºè·¨å¼‚æ„æ¨¡æ€è¿›è¡Œå¯¹æ¯”å­¦ä¹ ï¼Œä½¿å¾—ä¸åŒæ¨¡æ€çš„è¡¨å¾èƒ½å¤Ÿå¯¹é½ã€‚2) ç‰‡æ®µæ„ŸçŸ¥æ—‹è½¬ä½ç½®ç¼–ç ï¼ˆF-RoPEï¼‰ï¼šç”¨äºåœ¨WSIä¸­ä¿ç•™ç©ºé—´ç»“æ„å’Œç»„ç»‡ç‰‡æ®µæ‹“æ‰‘ã€‚3) é¢†åŸŸä¸“ç”¨å†…éƒ¨åŸºç¡€æ¨¡å‹ï¼šä¸ºWSIå’ŒRNA-seqæä¾›ç”Ÿç‰©å­¦åŸºç¡€çš„åµŒå…¥ï¼Œä»è€Œå®ç°ç¨³å¥çš„å¤šæ¨¡æ€å¯¹é½ã€‚æ•´ä½“æµç¨‹æ˜¯é¦–å…ˆä½¿ç”¨é¢†åŸŸä¸“ç”¨æ¨¡å‹æå–å„æ¨¡æ€çš„ç‰¹å¾ï¼Œç„¶åä½¿ç”¨F-RoPEç¼–ç WSIçš„ç©ºé—´ä¿¡æ¯ï¼Œæœ€åé€šè¿‡å¤šæ¨¡æ€SigLIPæŸå¤±è¿›è¡Œè”åˆè®­ç»ƒã€‚

**å…³é”®åˆ›æ–°**ï¼šè¯¥è®ºæ–‡çš„å…³é”®åˆ›æ–°åœ¨äºä»¥ä¸‹å‡ ä¸ªæ–¹é¢ï¼š1) æå‡ºäº†å¤šæ¨¡æ€SigLIPæŸå¤±ï¼Œèƒ½å¤Ÿæœ‰æ•ˆåœ°è¿›è¡Œè·¨å¼‚æ„æ¨¡æ€çš„å¯¹æ¯”å­¦ä¹ ã€‚2) æå‡ºäº†ç‰‡æ®µæ„ŸçŸ¥æ—‹è½¬ä½ç½®ç¼–ç ï¼ˆF-RoPEï¼‰ï¼Œèƒ½å¤Ÿæ›´å¥½åœ°ä¿ç•™WSIä¸­çš„ç©ºé—´ç»“æ„å’Œç»„ç»‡ç‰‡æ®µæ‹“æ‰‘ã€‚3) æ„å»ºäº†é¢†åŸŸä¸“ç”¨çš„å†…éƒ¨åŸºç¡€æ¨¡å‹ï¼Œèƒ½å¤Ÿä¸ºWSIå’ŒRNA-seqæä¾›ç”Ÿç‰©å­¦åŸºç¡€çš„åµŒå…¥ã€‚è¿™äº›åˆ›æ–°ä½¿å¾—æ¨¡å‹èƒ½å¤Ÿæ›´å…¨é¢åœ°ç†è§£è‚¿ç˜¤çš„ç”Ÿç‰©å­¦ç‰¹æ€§ï¼Œä»è€Œæé«˜äº†æ¨¡å‹çš„æ€§èƒ½ã€‚

**å…³é”®è®¾è®¡**ï¼šå¤šæ¨¡æ€SigLIPæŸå¤±é‡‡ç”¨æ‰€æœ‰æˆå¯¹çš„å¯¹æ¯”å­¦ä¹ ï¼Œé¼“åŠ±æ¥è‡ªåŒä¸€æ‚£è€…çš„ä¸åŒæ¨¡æ€çš„åµŒå…¥å½¼æ­¤é è¿‘ï¼Œè€Œæ¥è‡ªä¸åŒæ‚£è€…çš„åµŒå…¥å½¼æ­¤è¿œç¦»ã€‚F-RoPEé€šè¿‡æ—‹è½¬ä½ç½®ç¼–ç æ¥ä¿ç•™ç©ºé—´ä¿¡æ¯ï¼Œå¹¶ä½¿ç”¨ç‰‡æ®µä¿¡æ¯æ¥å¢å¼ºä½ç½®ç¼–ç ã€‚é¢†åŸŸä¸“ç”¨å†…éƒ¨åŸºç¡€æ¨¡å‹é’ˆå¯¹WSIå’ŒRNA-seqåˆ†åˆ«è¿›è¡Œé¢„è®­ç»ƒï¼Œä»¥è·å¾—æ›´å¥½çš„ç‰¹å¾æå–èƒ½åŠ›ã€‚å…·ä½“çš„å‚æ•°è®¾ç½®å’Œç½‘ç»œç»“æ„åœ¨è®ºæ–‡ä¸­æœ‰è¯¦ç»†æè¿°ï¼Œä½†æ­¤å¤„æœªæä¾›ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

EXAONE Path 2.5åœ¨Patho-BenchåŸºå‡†æµ‹è¯•ä¸­å–å¾—äº†ä¸æœ€å…ˆè¿›çš„åŸºç¡€æ¨¡å‹ç›¸å½“çš„æ€§èƒ½ï¼ŒåŒæ—¶åœ¨å†…éƒ¨ä¸´åºŠæ•°æ®é›†ä¸­è¡¨ç°å‡ºæ›´é«˜çš„é€‚åº”æ€§ã€‚è¿™è¡¨æ˜è¯¥æ¨¡å‹å…·æœ‰è‰¯å¥½çš„æ³›åŒ–èƒ½åŠ›å’Œä¸´åºŠåº”ç”¨æ½œåŠ›ã€‚è¯¥æ¨¡å‹è¿˜å…·æœ‰é«˜æ•°æ®å’Œå‚æ•°æ•ˆç‡ï¼Œèƒ½å¤Ÿåœ¨æœ‰é™çš„æ•°æ®é›†ä¸Šå–å¾—è‰¯å¥½çš„æ€§èƒ½ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

EXAONE Path 2.5åœ¨ç²¾å‡†è‚¿ç˜¤å­¦é¢†åŸŸå…·æœ‰å¹¿æ³›çš„åº”ç”¨å‰æ™¯ï¼Œå¯ä»¥ç”¨äºè‚¿ç˜¤è¯Šæ–­ã€é¢„åé¢„æµ‹å’Œæ²»ç–—æ–¹æ¡ˆé€‰æ‹©ã€‚é€šè¿‡æ•´åˆå¤šç»„å­¦ä¿¡æ¯ï¼Œè¯¥æ¨¡å‹èƒ½å¤Ÿæ›´å…¨é¢åœ°ç†è§£è‚¿ç˜¤çš„ç”Ÿç‰©å­¦ç‰¹æ€§ï¼Œä»è€Œä¸ºä¸´åºŠåŒ»ç”Ÿæä¾›æ›´å‡†ç¡®çš„å†³ç­–æ”¯æŒã€‚æœªæ¥ï¼Œè¯¥æ¨¡å‹è¿˜å¯ä»¥åº”ç”¨äºæ–°è¯ç ”å‘ï¼ŒåŠ é€Ÿç²¾å‡†åŒ»ç–—çš„å‘å±•ã€‚

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> Cancer progression arises from interactions across multiple biological layers, especially beyond morphological and across molecular layers that remain invisible to image-only models. To capture this broader biological landscape, we present EXAONE Path 2.5, a pathology foundation model that jointly models histologic, genomic, epigenetic and transcriptomic modalities, producing an integrated patient representation that reflects tumor biology more comprehensively. Our approach incorporates three key components: (1) multimodal SigLIP loss enabling all-pairwise contrastive learning across heterogeneous modalities, (2) a fragment-aware rotary positional encoding (F-RoPE) module that preserves spatial structure and tissue-fragment topology in WSI, and (3) domain-specialized internal foundation models for both WSI and RNA-seq to provide biologically grounded embeddings for robust multimodal alignment. We evaluate EXAONE Path 2.5 against six leading pathology foundation models across two complementary benchmarks: an internal real-world clinical dataset and the Patho-Bench benchmark covering 80 tasks. Our framework demonstrates high data and parameter efficiency, achieving on-par performance with state-of-the-art foundation models on Patho-Bench while exhibiting the highest adaptability in the internal clinical setting. These results highlight the value of biologically informed multimodal design and underscore the potential of integrated genotype-to-phenotype modeling for next-generation precision oncology.

